DSIP (Delta Sleep-Inducing Peptide): What the Research Shows

What Is DSIP?

DSIP is a nonapeptide, meaning it is built from nine amino acids. Swiss researchers M. Monnier and G.A. Schoenenberger at the University of Basel identified it in the 1970s using a technique called cross-circulation: blood from a sleeping, brain-stimulated rabbit was perfused into an awake rabbit, which then showed signs of induced sleep. When the team isolated and synthesized the responsible molecule, they reported an increase in delta EEG activity in test animals.

DSIP is found endogenously in the human hypothalamus, pituitary gland, limbic system, and even in breast milk, which has led some researchers to speculate it may play a role in sleep onset in newborns. It is not a drug, not synthesized by any pharmaceutical manufacturer for clinical use, and not approved or cleared by the FDA for any indication. It circulates today as a research chemical.

The Science: What Researchers Have Proposed

Research on DSIP peaked in the 1980s and early 1990s. Three broad areas of proposed activity have been discussed in the literature, though evidence for each carries important caveats.

### Sleep Regulation

Early animal studies suggested DSIP promotes slow-wave (delta) sleep without acting as a sedative in the traditional pharmacological sense. Some researchers described it as a "sleep modulator" rather than a sleep inducer, noting greater apparent activity in subjects with disturbed sleep compared to healthy sleepers. A small number of human studies followed. A 1981 trial reported increased sleep time and reduced wakefulness in a handful of volunteers given intravenous DSIP. A double-blind study of chronic insomnia patients published in the early 1990s found higher sleep efficiency in the DSIP group, but the investigators themselves characterized the statistically significant effects as weak and noted that a change in the placebo group may have inflated the apparent difference. A review published in Pharmacology, Biochemistry and Behavior described DSIP as "a still unresolved riddle," noting the absence of an identified DSIP receptor or gene.

### HPA Axis and Cortisol Modulation

Some research has examined DSIP's interactions with the hypothalamic-pituitary-adrenal (HPA) axis. DSIP co-localizes with ACTH in the pituitary gland, and animal studies have suggested it may modulate ACTH secretion and downstream cortisol production. A series of small human trials in the early 1980s reported that subjects receiving DSIP described greater relaxation and blunted stress responses. However, at least one controlled study found that DSIP did not meaningfully affect CRH- or meal-induced ACTH and cortisol secretion, illustrating the inconsistency across the literature.

### Analgesia

DSIP has been studied for analgesic properties, proposed to arise from interactions with opioid receptor pathways. Anticonvulsant activity has also been reported in animal models. Again, no high-quality human trial has confirmed these effects.

Honest Evidence Summary

|---|---|---|---|

The honest bottom line: DSIP is a biologically interesting molecule with a plausible theoretical framework, but the clinical evidence base is thin, old, and frequently contradictory. Modern sleep research has not revisited it with large, rigorous, placebo-controlled trials. A 2024 study published in Frontiers in Pharmacology explored a modified DSIP fusion peptide in sleep-deprived mice, finding it corrected neurotransmitter imbalances more effectively than DSIP alone, which signals continued preclinical interest. That work was done in rodents, not humans, and is not a basis for clinical conclusions.

The Tracking Angle: Why Wearable Sleep Metrics Matter Here

This is where MyProtocolStack brings practical value. Whether you are working with a licensed provider who tracks your sleep protocol or you are an independent optimizer building your own baseline data, wearable sleep metrics give you an objective signal that personal impression cannot.

Most modern wearables report several core metrics each morning:

MyProtocolStack imports this data from compatible devices and allows you to log notes, protocol starts, and other context alongside each night's numbers. If you and your provider are examining how any supplement, lifestyle intervention, or sleep hygiene change correlates with your sleep architecture over a 4 to 8 week window, you have a continuous, timestamped record, not just memory. You can also track lab [biomarkers like hs-CRP](/biomarkers/hs-crp) alongside wearable data for a more complete picture of recovery status.

This tracking-first framework is the right approach for any compound where the human evidence is limited, including DSIP. Objective data removes the noise of placebo effect and recall bias.

How DSIP Compares to Other Sleep-Adjacent Peptides

DSIP is often grouped by researchers with other peptides investigated for sleep and recovery. For context:

None of these peptides are FDA-approved for sleep indications, and all share the common challenge of limited large-scale human trial data. You can explore the broader [peptide research landscape here](/peptides) or review tracked [biomarker panels here](/biomarkers).

What the Research Cannot Tell Us Yet

The most significant gap in DSIP research is mechanistic: there is no confirmed DSIP-specific receptor. Without it, researchers cannot fully explain how or why DSIP would alter sleep architecture, modulate cortisol, or produce analgesia. The absence of a receptor also makes it difficult to design targeted follow-up studies.

The original human trials involved very small samples, primarily used intravenous administration (not the routes most commonly discussed today), and were conducted before modern polysomnography and wearable standards existed. Replicating those trials with today's methodology and larger cohorts would be necessary before drawing firm conclusions.

If you follow [IGF-1](/biomarkers/igf-1) as a marker of growth hormone activity or track hs-CRP for systemic inflammation, those panels can provide additional context when a provider is evaluating any peptide protocol. Explore the full [biomarker library here](/biomarkers).

Frequently Asked Questions

What is DSIP (delta sleep-inducing peptide)?

DSIP is a nine-amino-acid neuropeptide first isolated from rabbit cerebral venous blood in the late 1970s. It is named for reported delta-wave EEG activity in early animal studies. It occurs naturally in the human hypothalamus, pituitary, and breast milk, though its receptor has never been confirmed and its physiological role remains debated.

Does DSIP work as a sleep aid in humans?

The human evidence is limited, dated, and inconsistent. Small 1980s trials reported modest improvements in sleep efficiency in people with disturbed sleep, but at least one double-blind study concluded that short-term DSIP use is "not likely to be of major therapeutic benefit" for chronic insomnia. No large, modern randomized controlled trials have validated its efficacy.

Is DSIP FDA-approved?

No. DSIP is classified as a research chemical and has not cleared FDA review for any indication. It should never be used outside the context of a discussion with a qualified, licensed healthcare professional.

What proposed effects beyond sleep has DSIP been studied for?

Researchers have proposed HPA axis modulation (potentially reducing ACTH and cortisol surges), analgesic effects via opioid receptor pathways, anticonvulsant properties, and neuroendocrine signaling. Most of this evidence comes from animal studies or very small human pilots and should not be interpreted as clinical guidance.

How can I objectively track sleep quality changes over time?

Wearables report sleep score, deep sleep duration, REM duration, HRV, and resting heart rate nightly. MyProtocolStack imports this data and lets you align it with your protocol timeline, so you and your provider can see trends rather than relying on subjective recall. Start logging at [MyProtocolStack](/auth/login?mode=signup).

Sources

1. Schoenenberger GA, Monnier M. "The delta EEG (sleep)-inducing peptide (DSIP): amino-acid analysis, sequence, synthesis and activity of the nonapeptide." Proc Natl Acad Sci USA, 1977.

2. Graf MV, Schoenenberger GA. "Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)." Pharmacol Ther, 1984.

3. Schneider-Helmert D. "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study." Neuropsychobiology, 1992.

4. Schneider-Helmert D, Schoenenberger GA. "Effects of DSIP in man. A clinical trial." Eur Neurol, 1983.

5. Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." Pharmacol Biochem Behav, 2006.

6. Cady RK, Cady SL. "Delta sleep-inducing peptide." Eur J Anaesthesiol, 2001.

7. Zhang Y, et al. "DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models." Front Pharmacol, 2024.

8. Pollard BJ, Bhatt MB. "Delta sleep-inducing peptide does not affect CRH- and meal-induced ACTH and cortisol secretion." Neuropeptides, 1994.

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. DSIP is not FDA-approved. Always consult a qualified and licensed healthcare professional before starting, changing, or stopping any supplement, peptide, or health protocol.*